Search

Search Constraints

You searched for: Author/Creator Prager, Gerald W.

Search Results

1. A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study. Issue 6 (16th October 2020)

2. A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study. Issue 6 (16th October 2020)

5. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. (October 2020)

6. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer. Issue 8 (31st July 2014)

7. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study. (January 2021)

8. Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma. Issue 7 (21st May 2020)

9. Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. Issue 5 (November 2015)

10. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform. (8th May 2020)